Insulin lispro Sanofi

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
07-07-2023
Summary of Product characteristics Summary of Product characteristics (SPC)
07-07-2023
Public Assessment Report Public Assessment Report (PAR)
22-09-2017

Active ingredient:

инсулин лиспро

Available from:

Sanofi Winthrop Industrie

ATC code:

A10AB04

INN (International Name):

insulin lispro

Therapeutic group:

Лекарства, използвани при диабет

Therapeutic area:

Захарен диабет

Therapeutic indications:

За лечение на възрастни и деца със захарен диабет, които се нуждаят от инсулин за поддържане на нормална глюкозна хомеостаза. Инсулин лиспро Sanofi е показан и за първоначалната стабилизация на захарния диабет.

Product summary:

Revision: 9

Authorization status:

упълномощен

Authorization date:

2017-07-19

Patient Information leaflet

                                34
Б. ЛИСТОВКА
35
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
ИНСУЛИН ЛИСПРО SANOFI 100 ЕДИНИЦИ/ML
ИНЖЕКЦИОНЕН РАЗТВОР ВЪВ ФЛАКОН
инсулин лиспро (insulin lispro)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ИЗПОЛЗВАТЕ ТОВА
ЛЕКАРСТВО,
ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар или
фармацевт.
-
Това лекарство е предписано лично на
Вас. Не го преотстъпвайте на други
хора. То може
да им навреди, независимо че
признаците на тяхното заболяване са
същите както Вашите.
-
Ако получите някакви нежелани
лекарствени реакции, уведомете Вашия
лекар или
фармацевт. Това включва и всички
възможни нежелани реакции, неописани
в тази
листовка. Вижте точка 4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
1.
Какво представлява Инсулин Лиспро Sanofi
и за какво се използва
2.
Какво трябва да знаете, преди да
използвате Инсулин Лиспро Sanofi
3.
Как да използвате Инсулин Лиспро Sanofi
4.
Възможни нежелани реакции
5.
Как да съхранявате Инсулин Лиспро Sanofi
6.
Съдържание на опаковката и
допълнителна информация
1.
КАКВО ПРЕДСТАВЛЯВА ИНСУЛИН ЛИСПРО 
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Инсулин Лиспро Sanofi 100 единици/ml
инжекционен разтвор във флакон
Инсулин Лиспро Sanofi 100 единици/ml
инжекционен разтвор в патрон
Инсулин Лиспро Sanofi 100 единици/ml
инжекционен разтвор в предварително
напълнена
писалка
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Един ml разтвор съдържа 100 единици
(еквивалентни на 3,5 mg) инсулин лиспро
(insilun
lispro)*.
Инсулин Лиспро Sanofi 100 единици/ml
инжекционен разтвор във флакон
Всеки флакон съдържа 10 ml, еквивалентни
на 1 000 единици инсулин лиспро.
Инсулин Лиспро Sanofi 100 единици/ml
инжекционен разтвор в патрон
Всеки патрон съдържа 3 ml, еквивалентни
на 300 единици инсулин лиспро.
Инсулин Лиспро Sanofi 100 единици/ml
инжекционен разтвор в предварително
напълнена
писалка
Всяка предварително напълнена
писалка съдържа 3 ml, еквивалентни на 300
единици инсулин
лиспро.
Всяка предварително напълнена
писалка доставя 1-80 единици на стъпки
по 1 единица.
* Произвежда се по рекомбинантна ДНК
технология в
_E.coli_
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Инсулин Лиспро Sanofi 100 единици/ml
инжекционен разтвор във флакон и в
                                
                                Read the complete document

Similar products

Active ingredient инсулин лиспро

инсулин лиспро

ATC code A10AB04

A10AB04

Marketed by Sanofi Winthrop Industrie

Sanofi Winthrop Industrie

INN (International Name) insulin lispro

insulin lispro

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 07-07-2023
Summary of Product characteristics Summary of Product characteristics Spanish 07-07-2023
Public Assessment Report Public Assessment Report Spanish 22-09-2017
Patient Information leaflet Patient Information leaflet Czech 07-07-2023
Summary of Product characteristics Summary of Product characteristics Czech 07-07-2023
Public Assessment Report Public Assessment Report Czech 22-09-2017
Patient Information leaflet Patient Information leaflet Danish 07-07-2023
Summary of Product characteristics Summary of Product characteristics Danish 07-07-2023
Public Assessment Report Public Assessment Report Danish 22-09-2017
Patient Information leaflet Patient Information leaflet German 07-07-2023
Summary of Product characteristics Summary of Product characteristics German 07-07-2023
Public Assessment Report Public Assessment Report German 22-09-2017
Patient Information leaflet Patient Information leaflet Estonian 07-07-2023
Summary of Product characteristics Summary of Product characteristics Estonian 07-07-2023
Public Assessment Report Public Assessment Report Estonian 22-09-2017
Patient Information leaflet Patient Information leaflet Greek 07-07-2023
Summary of Product characteristics Summary of Product characteristics Greek 07-07-2023
Public Assessment Report Public Assessment Report Greek 22-09-2017
Patient Information leaflet Patient Information leaflet English 07-07-2023
Summary of Product characteristics Summary of Product characteristics English 07-07-2023
Public Assessment Report Public Assessment Report English 22-09-2017
Patient Information leaflet Patient Information leaflet French 07-07-2023
Summary of Product characteristics Summary of Product characteristics French 07-07-2023
Public Assessment Report Public Assessment Report French 22-09-2017
Patient Information leaflet Patient Information leaflet Italian 07-07-2023
Summary of Product characteristics Summary of Product characteristics Italian 07-07-2023
Public Assessment Report Public Assessment Report Italian 22-09-2017
Patient Information leaflet Patient Information leaflet Latvian 07-07-2023
Summary of Product characteristics Summary of Product characteristics Latvian 07-07-2023
Public Assessment Report Public Assessment Report Latvian 22-09-2017
Patient Information leaflet Patient Information leaflet Lithuanian 07-07-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 07-07-2023
Public Assessment Report Public Assessment Report Lithuanian 22-09-2017
Patient Information leaflet Patient Information leaflet Hungarian 07-07-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 07-07-2023
Public Assessment Report Public Assessment Report Hungarian 22-09-2017
Patient Information leaflet Patient Information leaflet Maltese 07-07-2023
Summary of Product characteristics Summary of Product characteristics Maltese 07-07-2023
Public Assessment Report Public Assessment Report Maltese 22-09-2017
Patient Information leaflet Patient Information leaflet Dutch 07-07-2023
Summary of Product characteristics Summary of Product characteristics Dutch 07-07-2023
Public Assessment Report Public Assessment Report Dutch 22-09-2017
Patient Information leaflet Patient Information leaflet Polish 07-07-2023
Summary of Product characteristics Summary of Product characteristics Polish 07-07-2023
Public Assessment Report Public Assessment Report Polish 22-09-2017
Patient Information leaflet Patient Information leaflet Portuguese 07-07-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 07-07-2023
Public Assessment Report Public Assessment Report Portuguese 22-09-2017
Patient Information leaflet Patient Information leaflet Romanian 07-07-2023
Summary of Product characteristics Summary of Product characteristics Romanian 07-07-2023
Public Assessment Report Public Assessment Report Romanian 22-09-2017
Patient Information leaflet Patient Information leaflet Slovak 07-07-2023
Summary of Product characteristics Summary of Product characteristics Slovak 07-07-2023
Public Assessment Report Public Assessment Report Slovak 22-09-2017
Patient Information leaflet Patient Information leaflet Slovenian 07-07-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 07-07-2023
Public Assessment Report Public Assessment Report Slovenian 22-09-2017
Patient Information leaflet Patient Information leaflet Finnish 07-07-2023
Summary of Product characteristics Summary of Product characteristics Finnish 07-07-2023
Public Assessment Report Public Assessment Report Finnish 22-09-2017
Patient Information leaflet Patient Information leaflet Swedish 07-07-2023
Summary of Product characteristics Summary of Product characteristics Swedish 07-07-2023
Public Assessment Report Public Assessment Report Swedish 22-09-2017
Patient Information leaflet Patient Information leaflet Norwegian 07-07-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 07-07-2023
Patient Information leaflet Patient Information leaflet Icelandic 07-07-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 07-07-2023
Patient Information leaflet Patient Information leaflet Croatian 07-07-2023
Summary of Product characteristics Summary of Product characteristics Croatian 07-07-2023
Public Assessment Report Public Assessment Report Croatian 22-09-2017

Search alerts related to this product

Alerts Insulin lispro Sanofi инсулин лиспро

Insulin lispro Sanofi инсулин лиспро

View documents history

Documents history Documents history

Insulin lispro Sanofi